



Dkt. 55672-A-PCT-US/JPW/BJA

1635

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gloria C. Li et al.

Serial No. : 09/750,410

Art Unit: 1635

Filed : December 28, 2000

Examiner: Jane Zara

For : USES OF DNA-PK

1185 Avenue of the Americas
New York, New York 10036
October 10, 2007

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the substitute PTO-1449 form attached hereto as **(Exhibit A)**. Copies of items 1-10 are attached hereto as **Exhibits 1-10**, respectively:

1. Extended European Search Report issued August 20, 2007 in connection with European Application No. 07 010 186.0 **(Exhibit 1)**;
2. U.S. Patent No. 5,641,754, issued to Iverson on June 24, 1997 **(Exhibit 2)**;
3. PCT International Publication No. WO 97/08184, Dana-Farber Cancer Institute, published March 6, 1997 **(Exhibit 3)**;
4. Gu, Yansong et al., (1997) "Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination," Proc. Natl. Acad. Sci. USA, 94:15, pgs.

Applicants : Gloria C. Li et al.
Serial No. : 09/750,410
Filed : December 28, 2000
Page 2 of 3

8076-8081 (**Exhibit 4**);

5. Jackson, Stephen, (1997) "DNA-dependent protein kinase," Int. J. Biochem. Cell Biol., 29:7, pgs. 935-938 (**Exhibit 5**);
6. Jin, Shengfang et al., (1998) "Differential etoposide sensitivity of cells deficient in the Ku and DNA-PKcs components of the DNA-dependent protein kinase," Carcinogenesis, 19:6, pgs. 965-971 (**Exhibit 6**);
7. Ouyang, Honghai et al., (1997) "Ku70 is required for DNA repair but not for T Cell antigen receptor gene recombination in vivo," J. Exp. Med, 186:6, pgs. 921-929 (**Exhibit 7**);
8. Shen, Hongxie et al., (1998) "Increased expression of DNA-dependent protein kinase confers resistance to adriamycin," Biochemica et Biophysica Acta, 1381:2, pgs. 131-138 (**Exhibit 8**);
9. Tseng, B.Y. et al., (1994) "Antisense oligonucleotide technology in the development of cancer therapeutics," Cancer Gene Therapy, 1:1, pgs. 65-71 (**Exhibit 9**); and
10. Uhlmann, Eugen et al., (1990) "Antisense oligonucleotides: a new therapeutic principle," Chemical Reviews, 90:4, pgs. 543-584 (**Exhibit 10**).

Items 2-10 were cited in an Extended European Search Report issued August 20, 2007 by the European Patent Office in connection with related European Patent Application No. 07010186.0. A copy of the Search Report is attached hereto as Exhibit 1.


Applicants : Gloria C. Li et al.
Serial No. : 09/750,410
Filed : December 28, 2000
Page 3 of 3

The Examiner is respectfully requested to make these references of record in the present application by initialing and returning a copy of the enclosed Form PTO 1449.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Pursuant to 37 C.F.R. §1.97(c)(2), a check for ONE HUNDRED AND EIGHTY DOLLARS (\$180.00) is enclosed. No additional fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

 10/10/07
John P. White Date
Reg. No. 28,678